ABSTRACT To investigate whether mast cell degranulation was important in producing nocturnal asthma, the effect of a single high dose of nebulised sodium cromoglycate on overnight bronchoconstriction, oxygen saturation, and breathing patterns in eight patients with nocturnal wheeze was examined. The study took the form of a double blind placebo controlled crossover comparison. Treatment with cromoglycate did not reduce the overnight fall in FEV1 or FVC, although it was associated with improved nocturnal oxygenation. This study suggests that mast cell degranulation may not be important in the pathogenesis of nocturnal asthma.
Patients with nocturnal asthma have been reported to have raised concentrations of plasma histamine at night.' This has been interpreted as indicating that mast cell degranulation is important in the production of overnight bronchoconstriction. If this is true then the mast cell stabilising agent sodium cromoglycate2 may specifically prevent nocturnal asthma. We have therefore studied the effect of a high dose of nebulised cromoglycate on overnight bronchoconstriction, oxygen saturation, and breathing patterns in patients with nocturnal asthma.
Methods
We studied eight patients (aged 18-62 years) with a history of regular nocturnal awakenings with wheeze and breathlessness (table). All had had symptoms of asthma in childhood. All had positive skin test responses to at least two common allergens; none was taking sodium cromoglycate, and none inhaled bronchodilators for at least six hours before each study. None had had an exacerbation of asthma for at least six weeks before the study and in all the FEV1 before sleep was within 15% of the value recorded at previous outpatient visits when they were in a stable clinical state.
The patients reported to the sleep laboratory on two pairs of two consecutive nights, seven to 14 days apart, the first of each pair of nights being for acclimatisation; data from the second of each pair only are reported. In a double blind randomised crossover 
Results
Overnight change in FEV1 and FVC In every patient FEV1 fell overnight after treatment with placebo (mean 2.5 (1.6)1 before sleep falling to 1.8 (1.7)1 on awakening; p < 0.05) but FEV1 also fell in all patients except one, in whom there was no change, with sodium cromoglycate (mean 2.4 (1.5) falling to 1.9 (1.2)1; p < 0.05: fig 1) . Similar changes occurred in FVC (3.8 (2.1) to 3.0 (1.8)1 with placebo; 3.9 (2.0) to 3.2 (1.8)1 with cromoglycate; p < 0.05 for both patients were awake (placebo 95 (2), cromoglycate 95% (3%)), the fall in oxygen saturation from the mean level when they were awake to the lowest saturation during sleep was significantly less during the cromoglycate night than during the placebo night (maximal fall in oxygen saturation 6% (3%) after cromoglycate, 8% (5%) after placebo; p < 0.05: fig 2) . Five of the eight subjects had fewer hypoxaemic episodes on the cromoglycate night but the number of episodes was unchanged in the other three (p > 0.05). Irregular breathing Sodium cromoglycate did not al-
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4. This study confirmed the observation that asthmatic patients become mildly hypoxaemic during sleep5 and showed that treatment with sodium cromoglycate was followed by improved nocturnal oxygenation. The means by which it improved oxygenation without changing FEV1 is unclear. There was no evidence that cromoglycate altered breathing patterns, although minor changes in ventilation between the two nights would not be detected by this technique. An alternative explanation is that cromoglycate might have dilated small airways, thus improving ventilation-perfusion matching while having no effect on large airway calibre, the principal determinant of FEV1.
This study shows that sodium cromoglycate is ineffective in the treatment of nocturnal asthma when given in a single high dose. The results do not support the theory that mast cell degranulation is central to the pathogenesis of nocturnal asthma. 
